A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467).
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs RG 4733 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 07 Oct 2013 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Jul 2012 Planned end date changed from 1 Apr 2011 to 1 Jan 2100 as reported by ClinicalTrials.gov.